GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Tax Expense

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Tax Expense : NT$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Tax Expense?

Great Novel Therapeutics Biotech & Medicals's tax expense for the months ended in Dec. 2023 was NT$0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.00 Mil.


Great Novel Therapeutics Biotech & Medicals Tax Expense Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Tax Expense Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial - - - - -

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Great Novel Therapeutics Biotech & Medicals Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Great Novel Therapeutics Biotech & Medicals Tax Expense Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines